Pre-Existing Humoral Immunological Memory Is Retained in Patients with Multiple Sclerosis Receiving Cladribine Therapy

Cladribine (CLAD) is a lymphodepleting agent approved for active relapsing multiple sclerosis (MS). The impact of CLAD on the adaptive humoral immune system has not sufficiently been studied. This study aimed to assess the influence of CLAD treatment on specific antibody titers to common pathogens....

Descripción completa

Detalles Bibliográficos
Autores principales: Moser, Tobias, O’Sullivan, Ciara, Puttinger, Christian, Feige, Julia, Pilz, Georg, Haschke-Becher, Elisabeth, Cadamuro, Janne, Oberkofler, Hannes, Hitzl, Wolfgang, Harrer, Andrea, Kraus, Jörg, Trinka, Eugen, Wipfler, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615381/
https://www.ncbi.nlm.nih.gov/pubmed/34829815
http://dx.doi.org/10.3390/biomedicines9111584

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615381/
https://www.ncbi.nlm.nih.gov/pubmed/34829815
http://dx.doi.org/10.3390/biomedicines9111584

Ejemplares similares